Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 4/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.31 |
| ▸ | RPA1 | P27694 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160063 | 0.86 | PTPN1 (0.47) | PTPN1PAX8F10MMP2PTPN2 | |
| SCHEMBL6228232 | 0.80 | PTPN1 (0.35) | PTPN1F10MMP2PTPN2CDC25B | |
| SCHEMBL29397485 | 0.74 | PTPN1 (0.44) | PTPN1PTPN2MEN1KMT2ACYP2C9 | |
| SCHEMBL12372508 | 0.73 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL24439949 | 0.72 | PTPN1 (0.43) | PTPN1PAX8F10MMP2PTPN2 | |
| SCHEMBL12547269 | 0.69 | PTPN1 (0.43) | PTPN1PAX8F10MMP2PTPN2 | |
| SCHEMBL9471834 | 0.69 | PTPN1 (0.43) | PTPN1PAX8F10MMP2PTPN2 | |
| SCHEMBL336573 | 0.69 | PTPN1 (0.43) | PTPN1PAX8F10MMP2PTPN2 | |
| SCHEMBL31438077 | 0.69 | PTPN1 (0.43) | PTPN1PAX8F10MMP2PTPN2 | |
| SCHEMBL678124 | 0.69 | PTPN1 (0.43) | PTPN1PAX8F10MMP2PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908934-B2 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20030125357-A1 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125357-A1 | Therapeutic compounds for treating dyslipidemic conditions | NR1H2, NR1H3, APOB | PTPN1 2938/4885PAX8 4825/4885F10 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.